Nancy Thornberry, Director at Denali Therapeutics Inc. (DNLI), sold 11,439 shares at $22.85 ($262K) on 2026-09-02, disclosed to the SEC on 2026-09-04.
Scheduled sale ($262k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $22.85 | 10,824 | $247K | 94.4% |
| 2 | $23.74 | 615 | $15K | 5.6% |
| Total | $22.90 avg | 11,439 | $262K | 100% |
| Filing → |